91360 Medical Technology Nanjing
A pathology information platform offering the latest news, policies, academic research, and learning resources for pathologists and medical professionals.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Series A | |
| Total Funding | 000k | ||
Related Content
91360 Medical Technology Nanjing Co., Ltd., founded in 2012 by Di Feng, operates at the intersection of digital pathology and artificial intelligence. Originally established as Jiangsu Kangke Yiruan Software Co., Ltd., the company officially changed its name in January 2018 to better reflect its focus. The firm is dedicated to addressing the challenges in China's pathology diagnostics market, which includes a significant shortage of qualified pathologists and uneven distribution of medical resources.
The company's core business revolves around providing comprehensive digital and intelligent solutions for pathology departments in medical institutions. Its business model centers on offering both software-as-a-service (SaaS) platforms and integrated hardware/software systems. Revenue is generated through the sale and service of these solutions to clients, which primarily consist of hospitals and other medical facilities. The company has successfully served nearly 40 medical institutions with its full digital informatization solution and over 200 users with its telepathology services.
91360 has developed a suite of products under the banners of 91360.com and 91360.ai. Key offerings include a digital pathology remote consultation platform, an AI-assisted diagnostic platform, and a comprehensive pathology information management system. This system covers the entire workflow of a pathology department, from appointment and process management to digital slide archiving, aiming to create a fully digital and traceable workflow. A significant component of its service is the 91360 Pathology Doctors Group, one of the first of its kind in China, which connects hospitals with top pathology experts for remote consultations, thereby improving diagnostic accuracy and efficiency. The company has also secured multiple rounds of financing from investors including Qianzhao Fund, demonstrating confidence in its technological and commercial capabilities.
Keywords: digital pathology, AI diagnostics, medical technology, pathology information systems, remote consultation, healthcare software, medtech, telepathology, pathology workflow, clinical decision support, cancer diagnostics, medical imaging AI, computational pathology, healthtech China, digital health, smart healthcare, pathology AI, tissue diagnostics, slide scanning, pathology informatics